B-Raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells

Cell Cycle

Volumn 3, Issue 2, 2004, Pages 189-196

  Shelton, John G ^a   Chang, Fumin ^a,b   Lee, John T ^a   Franklin, Richard A ^a   Steelman, Linda S ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; B Raf; Cell cycle progression; PI3K; Signal transduction

Indexed keywords

B RAF KINASE; ESTRADIOL; ESTROGEN RECEPTOR; INSULIN; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; CYTOKINE; RAF PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL DIVISION; HEMATOPOIETIC STEM CELL; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CYTOKINES; HEMATOPOIETIC STEM CELLS; INSULIN; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 3843138659     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Chang F, McCubrey JA. p21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001; 20:4354-64.
2. Chang F, Steelman, LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002; 1:220-6.
3. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch E, McMahon M, McCubrey JA. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000; 14:642-6.
4. McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, Pearce M, White MK, Franklin R, Blalock WL. Effects of deregulated Raf and MEK1 expression on the cytokine-dependency of hematopoietic cells. Adv Enzyme Regul 2000; 40:305-37.
5. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M, McCubrey JA. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 2003; 17:1765-82.
6. Henriksson M, Barkardjiev A, Klein G, Luscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 1993; 8:3199-209.
7. Seth A, Gonzlez FA, Gupta S, Raden DL, Davis RJ. Signal transduction within the nucleus by mitogen-activated protein kinase. J Biol Chem 1992; 267:24796-804.
8. Yang B, Hauser CA, Henkel G, Colman MS, van Beveren C, Stacey KJ, Hume DA, Maki RA, Ostrowski MC. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 1996; 16:538-47.
9. McCarthy SA, Chen D, Yang BS, Garcia Ramirez JJ, Cherwinski H, Chen XR, Klagsbrun M, Hauser CA, Ostrowski MC, McMahon M. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol Cell Biol 1997; 17:2401-12.
10. Smeal T, Binetruy B, Mercola DA, Grover-Bardwick A, Heidecker G, Rapp UR, Karin M. Oncoprotein-mediated signaling cascade stimulates c-Jun activity by phosphorylation of serine 63 and 73. Mol Cell Biol 1992; 12:3507-13.
11. Chou SY, Baichwal V, Ferrell JE Jr. Inhibition of c-Jun DNA binding by mitogen-activated protein kinase. Mol Biol Cell 1993; 3:1117-30.
12. Böhm M, Moellmann G, Cheng E, Alvarez FM, Wagner S, Sassone-Corsi P, Halaban R. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995; 6:291-302.
13. Lian JP, Huang R, Robinson D, Badwey JA. Activation of p90RSK and cAMP response element binding protein in stimulated neutrophils: novel effects of the pyridinyl imidazole SB 203580 on activation of the extracellular signal-regulated kinase cascade. J Immunol 1999; 163:4527-36.
14. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal Transduction Mediated by the Ras/Raf/MEK/ERK Pathway From Cytokine Receptors to Transcription Factors: Potential Targeting for Therapeutic Intervention. Leukemia 2003; 17:1263-93.
15. Papin C, Denouel A, Calothy G, Eychene A. Identification of signaling proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene 1996; 12:2213-21.
16. Wu X, Noh SJ, Zhou G, Dixon JE, Guan KL. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J Biol Chem 1996; 271:3265-71.
17. Huang W, Kessler DS, Erikson RL. Biochemical and biological analysis of MEK1 phosphorylation site mutants. Mol Biol Cell 1995; 6:237-45.
18. Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH-3T3 cells. Mol Cell Biol 1995; 15:6430-42.
19. Muszynski KW, Ruscetti FW, Heidecker G, Rapp UR, Troppmair J, Gooya, JM et al. Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells. J Exp Med 1995; 181:2189-99.
20. Marais R, Light Y, Peterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997; 272:4378-83.
21. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17:5598-611.
22. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M, McCubrey JA. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoeitic cells. Oncogene 2000; 19:526-36.
23. Vale T, Ngo TT, White MA, Lipsky PE. BRaf-induced transformation requires an interleukin 1 autocrine loop. Cancer Res 2001; 61:602-7.
24. Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun X-M, Brown J, Marais R, Pritchard C. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001; 20:1940-51.
25. Mikula M, Schreiber M, Husak Z, Kucerova L, Rüth J, Wieser R, Zatloukal K, Beug H, Wagner EF, Baccarini M. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf gene. EMBO J 2001; 20:1952-62.
26. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A. Endothelial apoptosis in B-Raf deficient mice. Nature Genet 1997; 16:293-7.
27. Wiese S, Pei G, Karch C, Troppmair J, Holtmann, B, Rapp UR, Zimmer A. Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons. Nature Neurosci. 2001; 4:137-42.
28. Baccarini M. An old kinase on a new path: Raf and apoptosis. Cell Death Differ 2002; 9:783-5
29. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281:1680-83.
30. Wang HG, Miyashita T, Takayama, S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L III, Troppmair J, Rapp UR, Reed JC. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994; 9:2751-6.
31. Tzivion G, Shen YH, Zhu J. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene. 2001; 20:6331-8.
32. Nantel A, Huber M, Thomas DY. Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf-1 pool. J Biol Chem 1999; 274:35719-24.
33. Le Mellay V, Troppmair J, Benz R, Rapp, UR. Negative regulation of mitochondrial VDAC channels by C-Raf kinase. BMC Cell Biol 2002; 3:14-25.
34. Baumann B, Weber CK, Troppmair J, Whiteside S, Isreal A, Rapp UR, Wirth T. Raf induces NF-kB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci USA 2000; 97:4615-20.
35. Chen J, Fujii K, Zhang L, Roberts T, Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001; 98:7783-8.
36. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/ERK pathway. Mol Cell Biol 1999; 19:5308-15.
37. Mercer K, Chiloeches A, Huser M, Kiernan M, Marais R, Pritchard C. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf. Oncogene 2002; 17:347-55.
38. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf, D. Growth factor-dependent hemopoietic precursor cell lines. J Exp Med 1980; 152:1036-47.
39. Franklin RA, Atherfold PA, McCubrey JA. Calcium-induced ERK activation in human T lymphocytes occurs via p56Lck and CaM-kinase. Molecular Immunology 2000; 37:675-83.
40. Howe CJ, LaHair MM, Maxwell JA, Lee JT, Robinson PJ, Rodriguez-Mora O, McCubrey JA, Franklin RA. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced IkB phosphorylation in human T lymphocytes. J Biol Chem 2002; 277:30469-76.
41. McCubrey JA, Steelman LS, Mayo MW, Algate PA, Dellow RA, Kaleko M. Growth Promoting Effects of Insulin-Like Growth Factor-1 on Hematopoietic Cells: Overexpression of introduced IGF-1 receptor abrogates IL-3-dependency of murine factor dependent cells by a ligand-dependent mechanism. Blood 1991; 78:921-9.
42. Blalock WL, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, and McCubrey JA. Requirement for the PI3K/Akt Pathway in MEK1-Mediated Growth and Prevention of Apoptosis: Identification of an Achilles Heel in Leukemia. Leukemia 2003; 17:1058-67.
43. Blalock WL, Pearce M, Chang F, Lee J, Pohnert S, Burrows C, Steelman LS, Franklin RA, McMahon M, and McCubrey J. Effects of inducible MEK1 activation on the cytokine-dependency of lymphoid cells. Leukemia 2001; 15:794-807.
44. Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M, McCubrey J. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine-dependency of human and murine hematopoietic cells. Leukemia 2000; 14:1080-96.
45. Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein- Oppenheimer C, Pearce M, Steelman L, McMahon M and McCubrey JA. Synergy between Raf and BCL2 in abrogating the cytokine-dependency of hematopoietic cells. Leukemia 2000; 14:1060-79.
46. von-Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, Berberich-Siebelt F, Rapp UR, Troppmair J. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 2001; 21:2324-36.
47. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231-41.
48. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-xL. Cell 1996; 87:619-28
49. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowas O, Miyazono K, Noda T, Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinase and apoptosis. EMBO Rep 2001; 2:222-8.
50. DeChant AK, Dee K, Weyman CM. Raf-induced effects on the differentiation and apoptosis of skeletal myoblasts are determined by the level of Raf signaling: abrogation of apoptosis by Raf is downstream of caspase 3 activation. Oncogene 2002; 21:5268-79.
51. Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, Calabretta B, Skorski T. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res 1999; 59:2815-9.
52. Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, Calabretta B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 1998; 187:1995-2007.
53. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19:7203-15.
54. Kalas W, Kisielow P, Strzadala L. Inhibition of MEK induces Fas expression and apoptosis in lymphomas overexpressing Ras. Leuk Lymphoma 2002; 43:1469-74.
55. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-31.
56. Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell 2002; 11:1103-12.
57. Peruzzi F, Prisco M, Morrione A, Valentinis B, Baserga R. Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4. J Biol Chem 2001; 276:25990-6.
58. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PM, Franklin RA, Pohnert SC, Mizra AM, McMahon M, and McCubrey JA. Effects of the Raf/MEK/ERK and PI3K signal transduction pathways on the abrogation of cytokine dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003; 24:2478-92.
59. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detec Prev 2001; 25:375-93.
60. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle P.E., Wang X.Y, Algate P.A, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13:1109-66.
61. Lee JT Jr, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia 2002; 16:486-507.
62. Chang F, Lee JT, Navolanic PM, Franklin RA, McCubrey JA, Steelman JG, Blalock WL, Franklin RA, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003; 17:590-603.
63. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PN, Blalock WL, Franklin RA and McCubrey JA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 2003; 22:469-80.
64. Larson RA, Daley GQ, Schiffer CA, Porcu P, Pui CH, Marie JE , Steelman LS, Bertrand F and McCubrey JA. Treatment by Design in Leukemia, a Meeting Report, Philadelphia, Pennsylvania, December 2002. Leukemia 2004; 18: In press.
65. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, RAF/MEK/ERK, PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis, Leukemia 2004; 18: In press.
66. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003; 17:2081-9.
67. Reuter CW, Catling AD, Jelinek T, Weber MJ. Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. J Biol Chem 1995; 270:7644-55.
68. Mizutani S, Inouye K, Koide H, Kaziro Y. Involvement of B-Raf in Ras-induced Raf-1 activation. FEBS Letters 2001; 507:295-8.
69. Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 2002; 531:475-82.
70. Gomez E, Pritchard C, Herbert TP. cAMP dependent protein kinase and Ca2+ influx through L-type voltage gated calcium channels mediate Raf independent activation of extracellular regulated kinase in response to glucagon like peptide-1 in pancreatic beta-cells. J. Biol. Chem. 2002; 277:48146-51.
71. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M. Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 12: 1998;1903-29.
72. Lee JT Jr, McCubrey JA. Targeting the Raf kinase cascade in cancer therapy-Novel molecular targets and therapeutic strategies. Expert Opinions Ther Targets 2002; 6:659-78.
73. Lee JT Jr, McCubrey JA. BAY 43-9006 Bayer Current Opinion in Investigational Drugs. 2003; 4:757-63.